RochesterJAKirchnerJT. Ecstasy (3,4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology. J Am Board Fam Pract. 1999;12(2):137–142.
2.
KalantH. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ. 2001;165:917–928.
3.
RogersGElstonJGarsideR. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess. 2009;13:iii–xii, 1.
WuLTParrottACRingwaltCLYangCBlazerDG. The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions. Am J Addict. 2009;18:452–461.
6.
HallAPHenryJA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96(6):678–685.
7.
ParrottAC. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl). 2004;173(3-4):234–241.
8.
SherlockKWolffKHayAWConnerM. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med. 1999;16(3):194–197.
9.
WolffKHayAWSherlockKConnerM. Contents of “ecstasy”. Lancet. 1995;346(8982):1100–1101.
10.
GoreSM. Fatal uncertainty: death-rate from use of ecstasy or heroin. Lancet. 1999;354:1265–1266.
11.
SchifanoFOyefesoAWebbLPollardMCorkeryJGhodseAH. Review of deaths related to taking ecstasy, England and Wales, 1997-2000. BMJ. 2003;326(7380):80–81.
12.
DowlingGPMcDonoughETIIIBostRO. ‘Eve’ and ‘Ecstasy’. A report of five deaths associated with the use of MDEA and MDMA. JAMA. 1987;257(12):1615–1617.
13.
GreeneSLDarganPIO'connorNJonesALKerinsM. Multiple toxicity from 3,4-methylenedioxymethamphetamine (“ecstasy”). Am J Emerg Med. 2003;21(2):121–124.
14.
HenryJAJeffreysKJDawlingS. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet. 1992;340(8816):384–387.
15.
ArmenianPMamantovTMTsutaokaBT. Multiple MDMA (Ecstasy) overdoses at a rave event: a case series [published online on May 28, 2012]. J Intensive Care Med. 2012.
16.
MuellerPDKoreyWS.Death by “ecstasy”: the serotonin syndrome?Ann Emerg Med. 1998;32(3 pt 1):377–380.
17.
FahalIHSallomiDFYaqoobMBellGM. Acute renal failure after ecstasy. BMJ. 1992;305:29.
18.
MallickABodenhamAR. MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accid Emerg Med. 1997;14(5):336–338.
19.
ScreatonGRSingerMCairnsHSThrasherASarnerMCohenSL. Hyperpyrexia and rhabdomyolysis after MDMA (“ecstasy”) abuse. Lancet. 1992;339(8794):677–678.
20.
SimpsonDLRumackBH. Methylenedioxyamphetamine. Clinical description of overdose, death, and review of pharmacology. Arch Intern Med. 1981;141:1507–1509.
21.
MilroyCM.“Ecstasy” associated deaths: what is a fatal concentration? Analysis of a case series. Forensic Sci Med Pathol. 2011;7(3):248–252.
22.
de laTorreFarreMRosetPN. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26(2):137–144.
23.
ParrottAC. MDMA and temperature: a review of the thermal effects of ‘Ecstasy’ in humans. Drug Alcohol Depend. 2012;121(1-2):1–9.
24.
BrownPLKiyatkinEA. Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. Eur J Neurosci. 2004;20(1):51–58.
25.
GrunauBEWiensMOBrubacherJR. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM. 2010;12(5):435–442.
